MYELOPROLIFERATIVE NEOPLASMS
Clinical trials for MYELOPROLIFERATIVE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE NEOPLASMS trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human trial launches for new blood cancer treatment
Disease control Recruiting nowThis is an early-stage study to test the safety and find the right dose of a new drug called INCA033989. It will be given alone or combined with an existing drug (ruxolitinib) to 230 people with myeloproliferative neoplasms, a group of blood cancers. The main goal is to see how w…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
First human test for promising blood cancer treatment
Disease control Recruiting nowThis is an early-stage study to test the safety and find the right dose of a new drug called INCA033989. It will be given alone or combined with an existing drug (ruxolitinib) to 225 people with certain blood cancers called myeloproliferative neoplasms. The main goal is to see ho…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
First patients to test experimental blood cancer drug
Disease control Recruiting nowThis is the first study in people to test a new drug called INCA036978 for myeloproliferative neoplasms, a group of rare blood cancers. The main goal is to find a safe dose and understand the drug's side effects in up to 218 participants with myelofibrosis, polycythemia vera, or …
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for tough blood cancers: first human trial begins
Disease control Recruiting nowThis is the first study in people to test a new drug called INCB160058 for myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The main goal is to find a safe dose and see how the body processes the drug in 186 adults whose current treatments have stopped working.…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for tough blood cancers: first human tests begin
Disease control Recruiting nowThis is the first study in people to test a new drug called INCA035784 for rare blood cancers called myeloproliferative neoplasms. The main goal is to find a safe dose and see what side effects it causes in 120 adults who have not responded well to other treatments. Researchers w…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
New drug duo tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of two drugs, ivosidenib and ruxolitinib, when used together. It is for adults with advanced blood cancers (called myeloproliferative neoplasms) that have a specific genetic change (IDH1 mutation). The main goal is to see…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC
-
Massive 5,000-Person study launches to map the journey of rare blood cancers
Knowledge-focused Recruiting nowThis is a long-term observational study aiming to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. who have been diagnosed with an MPN for at least five years, collecting information from …
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:40 UTC